These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30980038)

  • 1. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.
    Hammarsten P; Josefsson A; Thysell E; Lundholm M; Hägglöf C; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Granfors T; Wikström P; Bergh A
    Mod Pathol; 2019 Sep; 32(9):1310-1319. PubMed ID: 30980038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy.
    Khoo VS; Pollack A; Cowen D; Joon DL; Patel N; Terry NH; Zagars GK; von Eschenbach AC; Meistrich ML; Troncoso P
    Prostate; 1999 Nov; 41(3):166-72. PubMed ID: 10517874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
    Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A
    Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
    Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
    Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.
    Thysell E; Vidman L; Ylitalo EB; Jernberg E; Crnalic S; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Widmark A; Rydén P; Bergh A; Wikström P
    Mol Oncol; 2019 Aug; 13(8):1763-1777. PubMed ID: 31162796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
    Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer.
    Danilewicz M; Stasikowska-Kanicka O; Wągrowska-Danilewicz M
    Pol J Pathol; 2015 Mar; 66(1):44-8. PubMed ID: 26017879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
    Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H
    Cancer; 2010 Jun; 116(11):2612-20. PubMed ID: 20336781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting.
    Hammarsten P; Dahl Scherdin T; Hägglöf C; Andersson P; Wikström P; Stattin P; Egevad L; Granfors T; Bergh A
    PLoS One; 2016; 11(10):e0164016. PubMed ID: 27764093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.
    Büscheck F; Sulimankhil M; Melling N; Höflmayer D; Hube-Magg C; Simon R; Göbel C; Hinsch A; Weidemann S; Izbicki JR; Jacobsen F; Mandelkow T; Blessin NC; Möller-Koop C; Lutz F; Viehweger F; Möller K; Sauter G; Lennartz M; Burandt E; Lebok P; Minner S; Bonk S; Huland H; Graefen M; Schlomm T; Fraune C
    Cancer Med; 2020 Feb; 9(4):1409-1418. PubMed ID: 31893572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
    Bonk S; Kluth M; Jansen K; Hube-Magg C; Makrypidi-Fraune G; Höflmayer D; Weidemann S; Möller K; Uhlig R; Büscheck F; Luebke AM; Burandt E; Clauditz TS; Steurer S; Schlomm T; Huland H; Heinzer H; Sauter G; Simon R; Dum D
    Prostate; 2020 Sep; 80(13):1097-1107. PubMed ID: 32628300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique Features of Prostate Cancer in African American and West Indian Patients Including Diagnosis of High Grade Cancers Using Only Elevated Serum Levels of Prostate Specific Antigen.
    Seydafkan S; Michl J; Pincus MR
    Ann Clin Lab Sci; 2020 Jul; 50(4):504-511. PubMed ID: 32826248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
    Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Young CY; Klee GG; Tindall DJ; Bostwick DG
    Urology; 1997 Jun; 49(6):857-62. PubMed ID: 9187691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes.
    Dudka I; Lundquist K; Wikström P; Bergh A; Gröbner G
    J Transl Med; 2023 Nov; 21(1):860. PubMed ID: 38012666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.
    Zabalza CV; Adam M; Burdelski C; Wilczak W; Wittmer C; Kraft S; Krech T; Steurer S; Koop C; Hube-Magg C; Graefen M; Heinzer H; Minner S; Simon R; Sauter G; Schlomm T; Tsourlakis MC
    Oncotarget; 2015 May; 6(14):12822-34. PubMed ID: 25825985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression.
    Hammarsten P; Cipriano M; Josefsson A; Stattin P; Egevad L; Granfors T; Fowler CJ
    PLoS One; 2012; 7(10):e47994. PubMed ID: 23133535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
    Mahal BA; Yang DD; Wang NQ; Alshalalfa M; Davicioni E; Choeurng V; Schaeffer EM; Ross AE; Spratt DE; Den RB; Martin NE; Mouw KW; Orio PF; Choueiri TK; Taplin ME; Trinh QD; Feng FY; Nguyen PL
    Eur Urol; 2018 Aug; 74(2):146-154. PubMed ID: 29478736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
    Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
    Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.